Boundless Bio, Inc.
BOLD
$1.15
-$0.02-1.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.92% | 18.68% | 30.04% | 45.91% | 48.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.26% | -1.39% | 9.80% | 23.72% | 33.71% |
| Operating Income | 13.26% | 1.39% | -9.80% | -23.72% | -33.71% |
| Income Before Tax | 10.96% | -1.15% | -11.55% | -23.61% | -32.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.96% | -1.15% | -11.55% | -23.61% | -32.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.96% | -1.15% | -11.55% | -23.61% | -32.22% |
| EBIT | 13.26% | 1.39% | -9.80% | -23.72% | -33.71% |
| EBITDA | 13.69% | 1.71% | -9.67% | -23.85% | -34.07% |
| EPS Basic | 82.07% | 88.25% | 91.38% | 93.13% | 64.30% |
| Normalized Basic EPS | 82.07% | 88.25% | 91.38% | 93.13% | 64.30% |
| EPS Diluted | 82.07% | 88.25% | 91.38% | 93.13% | 64.30% |
| Normalized Diluted EPS | 82.07% | 88.25% | 91.38% | 93.13% | 64.30% |
| Average Basic Shares Outstanding | 31.88% | 90.96% | 246.33% | 1,699.90% | 1,294.88% |
| Average Diluted Shares Outstanding | 31.88% | 90.96% | 246.33% | 1,699.90% | 1,294.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |